Showing results (211-220 of 245) with videos related to

Sort By:
Pageof 25
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.
Hepatology Communications|April 28, 2022
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCCRohini Sharma, Anjana Pillai, Thomas Urban Marron, et al.
Hepatology International|April 3, 2023
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinomaMathew Vithayathil, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 20, 2022
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinomaMathew Vithayathil, Antonio D'Alessio, Claudia A M Fulgenzi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinibMargherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Liver Cancer|December 24, 2021
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular CarcinomaPetros Fessas, Muntaha Naeem, Matthias Pinter, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational studyThomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Hepatology (Baltimore, Md.)|March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world studyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
World Journal of Gastrointestinal Oncology|December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinomaSirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Cancers|December 11, 2022
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus BevacizumabYue Linda Wu, Claudia Angela Maria Fulgenzi, Antonio D'Alessio, et al.
Pageof 25